Antibiotic Restriction Might Facilitate the Emergence of Multi-drug Resistance

PLoS Computational Biology

Volumn 11, Issue 6, 2015, Pages

  Obolski, Uri ^a   Stein, Gideon Y ^b   Hadany, Lilach ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; DRUG THERAPY;

ANTIBIOTIC PRODUCTION; ANTIBIOTICS RESISTANCE; BACTERIA-RESISTANT; BACTERIAL INFECTIONS; DRUG-RESISTANT BACTERIA; MEDICAL CENTER; MULTIDRUG RESISTANCE; PUBLIC HEALTH ISSUES;

ANTIBIOTICS;

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CONTROLLED STUDY; DRUG RESTRICTION; DRUG USE; HUMAN; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; NONHUMAN; PRESCRIPTION; BACTERIAL INFECTIONS; BIOLOGICAL MODEL; BIOLOGY; DRUG EFFECTS; MICROBIOLOGY; TRANSMISSION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MODELS, BIOLOGICAL;

EID: 84953301055     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004340     Document Type: Article

References (46)

1. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, et al. (2013) Antibiotic resistance—the need for global solutions. The Lancet infectious diseases 13: 1057–1098. doi: 10.1016/S1473-3099(13)70318-9 24252483
2. Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, et al. (2012) Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clinical Microbiology and Infection 18: 413–431. doi: 10.1111/j.1469-0691.2012.03821.x 22507109
3. Kraker M, Jarlier V, Monen J, Heuer O, Sande N, et al. (2013) The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clinical Microbiology and Infection 19: 860–868. doi: 10.1111/1469-0691.12028 23039210
4. Maragakis LL, Perencevich EN, Cosgrove SE, (2008) Clinical and economic burden of antimicrobial resistance. doi: 10.1586/14787210.6.5.751 18847410
5. De Kraker ME, Davey PG, Grundmann H, Group BS, (2011) Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS medicine 8: e1001104. doi: 10.1371/journal.pmed.1001104 22022233
6. Peralta G, Sánchez MB, Garrido JC, De Benito I, Cano ME, et al. (2007) Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. Journal of antimicrobial chemotherapy 60: 855–863. 17644532
7. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y, (2006) Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrobial agents and chemotherapy 50: 43–48. 16377665
8. Nseir S, Di Pompeo C, Cavestri B, Jozefowicz E, Nyunga M, et al. (2006) Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome*. Critical care medicine 34: 2959–2966. 17012911
9. McGowan JE, Jr (2006) Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. The American journal of medicine 119: S29–S36. 17059911
10. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, et al. (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet infectious diseases 10: 597–602. doi: 10.1016/S1473-3099(10)70143-2 20705517
11. Levy SB, Marshall B, (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nature medicine 10: S122–S129. 15577930
12. Leeb M, (2004) Antibiotics: a shot in the arm. Nature 431: 892–893. 15496888
13. Rodríguez-Rojas A, Rodríguez-Beltrán J, Couce A, Blázquez J, (2013) Antibiotics and antibiotic resistance: a bitter fight against evolution. International Journal of Medical Microbiology 303: 293–297. doi: 10.1016/j.ijmm.2013.02.004 23517688
14. McClure NS, Day T (2014) A theoretical examination of the relative importance of evolution management and drug development for managing resistance. Proceedings of the Royal Society B: Biological Sciences 281: 20141861.
15. Shlaes DM, Sahm D, Opiela C, Spellberg B, (2013) The FDA Reboot of Antibiotic Development. Antimicrobial agents and chemotherapy 57: 4605–4607. doi: 10.1128/AAC.01277-13 23896479
16. Boucher HW, Talbot GH, Benjamin DK, Bradley J, Guidos RJ, et al. (2013) 10×'20 Progress—development of new drugs active against gram-negative bacilli: an update from the infectious diseases society of america. Clinical infectious diseases 56: 1685–1694. doi: 10.1093/cid/cit152 23599308
17. POLICY IP, (2010) The 10 ‘20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clinical Infectious Diseases 50: 1081–1083. doi: 10.1086/652237 20214473
18. Singer RS, Finch R, Wegener HC, Bywater R, Walters J, et al. (2003) Antibiotic resistance—the interplay between antibiotic use in animals and human beings. The Lancet infectious diseases 3: 47–51. 12505035
19. Wellington EM, Boxall A, Cross P, Feil EJ, Gaze WH, et al. (2013) The role of the natural environment in the emergence of antibiotic resistance in Gram-negative bacteria. The Lancet infectious diseases 13: 155–165. doi: 10.1016/S1473-3099(12)70317-1 23347633
20. Medicine JH (2013) Antibiotic Guidelines 2013–2014. http://www.hopkinsmedicine.org/amp/guidelines/Antibiotic_guidelines.pdf.
21. Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S, (2009) Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS medicine 6: e1000085. doi: 10.1371/journal.pmed.1000085 19440354
22. Joyner ML, Manning CC, Canter BN, (2012) Modeling the effects of introducing a new antibiotic in a hospital setting: A case study. Mathematical biosciences and engineering: MBE 9: 601–625. doi: 10.3934/mbe.2012.9.601 22881028
23. Bonhoeffer S, Lipsitch M, Levin BR, (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proceedings of the National Academy of Sciences 94: 12106–12111. 9342370
24. Lipsitch M, Bergstrom CT, Levin BR, (2000) The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proceedings of the National Academy of Sciences 97: 1938–1943. 10677558
25. Bergstrom CT, Lo M, Lipsitch M, (2004) Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proceedings of the National Academy of Sciences of the United States of America 101: 13285–13290. 15308772
26. Obolski U, Hadany L, (2012) Implications of stress-induced genetic variation for minimizing multidrug resistance in bacteria. BMC medicine 10: 89. doi: 10.1186/1741-7015-10-89 22889082
27. zur Wiesch PA, Kouyos R, Abel S, Viechtbauer W, Bonhoeffer S, (2014) Cycling empirical antibiotic therapy in hospitals: meta-analysis and models. PLoS pathogens 10: e1004225. doi: 10.1371/journal.ppat.1004225 24968123
28. Austin DJ, Bonten MJ, Weinstein RA, Slaughter S, Anderson RM, (1999) Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proceedings of the National Academy of Sciences 96: 6908–6913. 10359812
29. Cooper B, Lipsitch M, (2004) The analysis of hospital infection data using hidden Markov models. Biostatistics 5: 223–237. 15054027
30. Fish DN, Piscitelli SC, Danziger LH, (1995) Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 15: 279–291.
31. Milatovic D, Braveny I, (1987) Development of resistance during antibiotic therapy. European journal of clinical microbiology 6: 234–244. 3305004
32. Ross JE, Anderegg TR, Sader HS, Fritsche TR, Jones RN, (2005) Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagnostic microbiology and infectious disease 52: 53–58. 15878443
33. Tamma PD, Robinson GL, Gerber JS, Newland JG, DeLisle CM, et al. (2013) Pediatric Antimicrobial Susceptibility Trends across the United States. Infection Control and Hospital Epidemiology 34: 1244–1251. doi: 10.1086/673974 24225608
34. Andrews JM, Testing BWPoS (2001) BSAC standardized disc susceptibility testing method. Journal of Antimicrobial Chemotherapy 48: 43–57. 11420336
35. http://data.worldbank.org/indicator/SH.MED.BEDS.ZS. Last Accessed 10.05.2014.
36. Cooper B, Medley G, Stone S, Kibbler C, Cookson B, et al. (2004) Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proceedings of the National Academy of Sciences of the United States of America 101: 10223–10228. 15220470
37. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, et al. (2003) Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. The American journal of medicine 115: 529–535. 14599631
38. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH, (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest Journal 118: 146–155.
39. Andersson DI, Hughes D, (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nature Reviews Microbiology 8: 260–271. doi: 10.1038/nrmicro2319 20208551
40. Björkman J, Nagaev I, Berg O, Hughes D, Andersson DI, (2000) Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287: 1479–1482. 10688795
41. Kouyos RD, zur Wiesch PA, Bonhoeffer S, (2011) On being the right size: the impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community. PLoS pathogens 7: e1001334. doi: 10.1371/journal.ppat.1001334 21533212
42. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L, (2014) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1.
43. García-Rey C, Aguilar L, Baquero F, Casal J, Dal-Ré R, (2002) Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. Journal of clinical microbiology 40: 159–164. 11773111
44. Alpuche C, Garau J, Lim V, (2007) Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. International journal of antimicrobial agents 30: 135–138.
45. Obolski U, Alon D, Hadany L, Stein GY, (2014) Resistance profiles of coagulase-negative staphylococci contaminating blood cultures predict pathogen resistance and patient mortality. Journal of Antimicrobial Chemotherapy: dku156.
46. Kouyos RD, zur Wiesch PA, Bonhoeffer S, (2011) Informed switching strongly decreases the prevalence of antibiotic resistance in hospital wards. PLoS computational biology 7: e1001094. doi: 10.1371/journal.pcbi.1001094 21390265